Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA, Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	$ (36,919)	$ (7,013)	$ (44,720)	$ (13,129)
Adjusted EBITDA from discontinued operations	1,117	2,700	2,557	4,716
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	(36,919)	(7,013)	(44,720)	(13,129)
Income tax (benefit) expense	(686)	52	(568)	130
Depreciation and amortization		6,639	7,331	13,463
Impairment charges	35,608		36,448
Settlement	1,448	500	1,448	500
Divestiture-related expense	66		112
Stock-based compensation expense	1,600	2,522	2,506	3,752
Adjusted EBITDA from discontinued operations	$ 1,117	$ 2,700	$ 2,557	$ 4,716